Advanced glycation end product-mediated matrix metalloproteinase-9 and apoptosis via renin-angiotensin system in type 2 diabetes

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 6, 2010, Pages 578-589

  Ishibashi, Toshiyuki ^a   Kawaguchi, Michiko ^a   Sugimoto, Koichi ^a   Uekita, Hironori ^a   Sakamoto, Nobuo ^a   Yokoyama, Keiko ^a   Maruyama, Yukio ^a,b   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b HOSHI GENERAL HOSPITAL   (Japan)

Author keywords

ACE; Diabetic vascular complications; Plaque destabilization; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; HEMOGLOBIN A1C; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; RAS PROTEIN;

AORTA; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NICK END LABELING; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CASE CONTROL STUDY; CORONARY BLOOD VESSEL; DIABETIC ANGIOPATHIES; METABOLISM; PATHOLOGY;

AORTA; APOPTOSIS; CASE-CONTROL STUDIES; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MATRIX METALLOPROTEINASE 9; PEPTIDYL-DIPEPTIDASE A; RAS PROTEINS; RECEPTORS, IMMUNOLOGIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 77954692343     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3590     Document Type: Article

References (34)

1. Qiao Q, Tuomilehto J, Borch-Johnsen K: Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia, 2003; 46: M17-M21
2. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care, 1999; 22: 920-924
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405-412
4. Monnier VM, Cerami A: Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science, 1981; 211: 491-493
5. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem, 1992; 267: 5133-5138
6. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R: Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol, 1993; 143: 1649-1656
7. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res, 2004; 63: 582-592
8. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res, 2002; 90: 251-262
9. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234
10. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 1998; 21: 1414-1431
11. Heistad DD: Unstable coronary-artery plaques. N Engl J Med, 2003; 349: 2285-2287
12. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 2001; 104: 365-372
13. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 2003; 23: 283-288
14. Geng YJ, Libby P: Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol, 2002; 22: 1370-1380
15. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000; 355: 253-259
16. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 2002; 359: 995-1003
17. WHO Study Group: Diabetes mellitus. World Health Organ Tech Rep Ser, 1985; 727: 7-98
18. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med, 1997; 157: 2413-2446
19. Shindo J, Ishibashi T, Yokoyama K, Nakazato K, Ohwada T, Shiomi M, Maruyama Y: Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in watanabe heritable hyperlipidemic rabbits. Circulation, 1999; 99: 2150-2156
20. Saito F, Kawaguchi M, Izumida J, Asakura T, Maehara K, Maruyama Y: Alteration in haemodynamics and pathological changes in the cardiovascular system during the development of Type 2 diabetes mellitus in OLETF rats. Diabetologia, 2003; 46: 1161-1169
21. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1995; 92: 1355-1374
22. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation, 2003; 108: 1070-1077
23. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 1998; 316: 823-828
24. Sone H, Katagiri A, Ishibashi S, Abe R, Saito Y, Murase T, Yamashita H, Yajima Y, Ito H, Ohashi Y, Akanuma Y, Yamada N; JD Study Group: Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res, 2002; 34: 509-515
25. Schieffer B, Bünte C, Witte J, Hoeper K, Böger RH, Schwedhelm E, Drexler H: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol, 2004; 44: 362-368
26. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation, 2000; 101: 1372-1378
27. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA: High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol, 2004; 286: F1039-F1045
28. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes, 2002; 51: 3274-3282
29. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res, 2001; 88: 1291-1298
30. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R: Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol, 2004; 24: 1266-1271
31. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int, 2002; 61: 31-39
32. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J: Myocyte death in streptozotocininduced diabetes in rats in angiotensin II-dependent. Lab Invest, 2000; 80: 513-527
33. Fukumoto H, Naito Z, Asano G, Aramaki T: Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb, 1998; 5: 29-35
34. Ehara S, Naruko T, Shirai N, Itoh A, Hai E, Sugama Y, Ikura Y, Ohsawa M, Okuyama T, Shirai N, Yamashita H, Itabe H, Haze K, Yoshiyama M, Ueda M: Small coronary calcium deposits and elevated plasma levels of oxidized low density lipoprotein are characteristic of acute myocardial infarction. J Atheroscler Thromb, 2008; 15: 75-81